Find NHLBI Clinical Trials

Search selected NHLBI-supported clinical trials and observational studies by condition, location, or age group. You can also view the complete list of NHLBI-funded studies at ClinicalTrials.gov.

Filter by: Close
Disease or Condition

FILTER BY KEYWORD

Showing 1 - 10 out of 20 results
Recruiting
The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.
Adult, Older Adult
Recruiting
New York
Do you or your child have a platelet, bleeding, or white blood cell disorder? This study is looking at people who have platelet or other blood disorders. The researchers will use a blood sample to look for problems with platelets and a possible genetic cause in the participant’s DNA or RNA. To participate in this study, you must be a child or adult who either is healthy or has a platelet disorder, coagulation disorder, or white blood cell disorder. This study is located in New York, New York.
All Ages
Accepting Healthy Volunteers
Recruiting
Maryland
Are you an adult willing to give blood samples? This study investigates ways to prevent blood clotting in people with sickle cell disease. In this population, blood clotting is the most common cause of vascular death after heart attack and stroke. Scientists are studying the blood of people with sickle cell disease and comparing it with the blood of people without sickle cell disease over 2 years. To participate in this study, you must be between the ages of 18 and 80 years old and willing to participate for up to 2 years. This study takes place in Bethesda, Maryland.
Adult, Older Adult
Accepting Healthy Volunteers
Recruiting
New York
The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 10 participants.
Adult
Recruiting
Ohio
The Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Study is an ancillary study from the parent study, DCM Precision Medicine Study. The rationale for the DCM-CMR study is to leverage cardiac magnetic resonance (CMR) imaging to detect earliest findings of DCM in the at-risk family members enrolled into the parent study.
Adult, Older Adult
Accepting Healthy Volunteers
Recruiting
New York
The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 10 participants.
Adult
Recruiting
Ohio
The Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Study is an ancillary study from the parent study, DCM Precision Medicine Study. The rationale for the DCM-CMR study is to leverage cardiac magnetic resonance (CMR) imaging to detect earliest findings of DCM in the at-risk family members enrolled into the parent study.
Adult, Older Adult
Accepting Healthy Volunteers
Recruiting
California
The EXCITE-HCM study is designed to evaluate the effect of moderate intensity exercise training versus usual physical activity on the improvement of HCM-related symptoms and cardiac function. Patients will be followed during a period of 24 weeks and assessments as physical examination, questionnaires, 12 lead ECGs, biomarker levels, echocardiogram, Cardiac Magnetic resonance, PET and CPET will be performed to evaluate their response to the intervention.
Adult, Older Adult